- Home
- MTCH vs ROIV Comparison
MTCH vs ROIV Comparison
Compare MTCH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTCH | ROIV |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 14.1B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | MTCH | ROIV |
|---|---|---|
| Price | $32.49 | $22.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $35.00 | $24.31 |
| AVG Volume (30 Days) | 3.0M | ★ 7.4M |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $3,469,367,000.00 | $20,329,000.00 |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $3.46 | $376.94 |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.39 | $8.73 |
| 52 Week High | $39.20 | $23.23 |
Technical Indicators
Market Signals| Indicator | MTCH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 71.54 |
| Support Level | $32.19 | $20.14 |
| Resistance Level | $34.35 | $21.48 |
| Average True Range (ATR) | 0.74 | 0.79 |
| MACD | -0.14 | 0.14 |
| Stochastic Oscillator | 11.72 | 85.33 |
Price Performance
Historical ComparisonAbout MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.